Biogen Idec and Abbott began enrollment in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX) in patients with relapsing-remitting multiple sclerosis (RRMS). The trial, called DECIDE, will investigate a subcutaneous formulation of daclizumab intended for monthly administration, which has the potential to provide a new immunomodulatory approach for treating MS. Abbott will receive a $30 million milestone payment for the enrollment of ...